San Diego-based NovaCardia--which is developing drugs for cardiovascular disease--has raised $48 million in its second round. Skyline Ventures and InterWest Partners led the round with previous investors Domain Associates, Forward Ventures, Montreux Equity Partners, and Versant Ventures taking part as well. "This financing underscores the excitement around KW-3902 as a promising treatment for patients with CHF," added Randall E. Woods, president and CEO of NovaCardia.
- see the release on the round